New search Hide text from Guidelines
N NERVOUS SYSTEMN04 ANTI-PARKINSON DRUGS
This group comprises preparations used in the treatment of Parkinsons disease and related conditions, including drug-induced parkinsonism.
| The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease. No separate DDDs are established for oral depot formulations. |
N04B DOPAMINERGIC AGENTS
N04BA Dopa and dopa derivatives
Combinations with decarboxylase inhibitors and other dopaminergic agents are classified here.
| The DDD for the combination of levodopa and decarboxylase inhibitor is based on the content of levodopa, see ATC index. |
N04BB Adamantane derivatives
N04BC Dopamine agonists
Bromocriptine used in parkinsonism is classified in this group (e.g. tablets of 5 mg and 10 mg). Low strength bromocriptine tablets (e.g. 2.5 mg) used as a prolactine inhibitor are classified in G02CB - Prolactine inhibitors.
Cabergoline used in parkinsonism is classified in this group (e.g. tablets of 1 mg). Low strength cabergoline tablets (0.5 mg) used as a prolactine inhibitor are classified in G02CB.
Lisuride in high strength formulations (e.g. 0.2 mg tablets), which is also used in the treatment of Parkinsonism, are classified in G02CB while lisuride in low strength formulations (e.g. 25 mcg tablets) are classified in N02CA.
N04BD Monoamine oxidase B inhibitors
N04BX Other dopaminergic agents
This group comprises dopaminergic agents which cannot be classified in the preceding groups.
The combination of levodopa, decarboxylase inhibitor and COMT inhibitor is classified in N04BA - Dopa and dopa derivatives.
Last updated: 2024-01-26